Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone Lymphoma

被引：0
|
作者：
Monga, Neerav
Garside, Jamie
O'Donovan, Peter
Quigley, Joan
Padhiar, Amie
Parisi, Lori
Tapprich, Christoph
Nastoupil, Loretta
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2783
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory marginal zone lymphoma
    Yamasaki, Satoshi
    Chihara, Dai
    Yoshida, Isao
    Kohda, Kyuhei
    Sawa, Masashi
    Ago, Hiroatsu
    Togitani, Kazuto
    Ohno, Yuju
    Tanaka, Junji
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Suzumiya, Junji
    Suzuki, Ritsuro
    [J]. ANNALS OF HEMATOLOGY, 2019, 98 (06) : 1521 - 1523
  • [42] Impact of Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Marginal Zone Lymphoma
    Yamasaki, Satoshi
    Chihara, Dai
    Yoshida, Isao
    Kohda, Kyuhei
    Sawa, Masashi
    Ago, Hiroatsu
    Togitani, Kazuto
    Ohno, Yuju
    Tanaka, Junji
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Suzumiya, Junji
    Suzuki, Ritsuro
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [43] Idelalisib monotherapy and durable responses in patients with relapsed or refractory marginal zone lymphoma (MZL)
    Martin, P.
    Armas, A.
    Gopal, A.
    Gyan, E.
    Wagner-Johnston, N.
    Walewski, J.
    Abella, S.
    Ye, W.
    Philip, B.
    Sorenson, B.
    de Vos, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 100 - 100
  • [44] Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
    Martin, Peter
    Armas, Armando
    Gopal, Ajay K.
    Gyan, Emmanuel
    Wagner-Johnston, Nina D.
    Walewski, Jan
    Abella, Steve
    Ye, Wei
    Philip, Betsy
    Sorenson, Bess
    de Vos, Sven
    [J]. BLOOD, 2015, 126 (23)
  • [45] Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
    Galaznik, Aaron
    Huelin, Rachel
    Stokes, Michael
    Guo, Yelan
    Hoog, Meredith
    Bhagnani, Tarun
    Bell, Jill
    Shou, Yaping
    [J]. FUTURE SCIENCE OA, 2018, 4 (07):
  • [46] TARGETED LITERATURE REVIEW OF COST-EFFECTIVENESS MODELS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
    Gaballa, S.
    Swami, S.
    Sharma, R.
    Bhardwaj, A.
    Mohseninejad, L.
    Xue, M.
    Yang, K.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S111 - S111
  • [47] EFFICACY AND SAFETY OF COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE CHRONOS-1 STUDY
    Zinzani, P. L.
    Santoro, A.
    Leppa, S.
    Demeter, J.
    Follows, G. A.
    Lenz, G.
    Kim, W. S.
    Mollica, L.
    Nagler, A.
    Diong, C. P.
    Provenciio, M.
    Stevens, D. A.
    Trevarthen, D.
    Maagnoli, M.
    Cupit, L.
    Yin, S.
    Hiemeyer, F.
    Garcia-Vargas, J.
    Childs, B. H.
    Dreyling, M.
    [J]. HAEMATOLOGICA, 2017, 102 : 314 - 315
  • [48] Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)
    Phillips, Tycel
    Avigdor, Abraham
    Gurion, Ronit
    Patti, Caterina
    Corradini, Paolo
    Tani, Monica
    Mehta, Amitkumar
    Lossos, Izidore S.
    Lossos, Izidore S.
    Zinzani, Pier Luigi Luigi
    Thieblemont, Catherine
    Jurczak, Wojciech
    Zheng, Fred
    Rappold, Erica
    Zhao, Wanying
    Johnson, Peter
    [J]. BLOOD, 2021, 138
  • [49] Clinical Use of Emerging Therapies in Relapsed or Refractory Follicular Lymphoma
    Leslie, Lori A.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 15 - 19
  • [50] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Dhillon, Sohita
    [J]. TARGETED ONCOLOGY, 2017, 12 (02) : 255 - 262
12345